The gene product is subject to alternative splicing selectively in cancer, which deletes exon 4 (to generate Osteopontin-c) from the unspliced form (called Osteopontin-a); Osteopontin-b (lacking exon 5) is absent from healthy and transformed breast tissue. The gene discussed is SPP1; the disease is cancer.